Business Context and Reporting Period
This Form 8-K was filed by iBio, Inc. on January 4, 2018. The report addresses a regulatory notification received from the NYSE American regarding the Company's continued listing status due to low share price.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing compliance rather than financial performance data.
Material Changes
- Listing Status: The Company received notification that its continued listing on the NYSE American is predicated on effecting a reverse stock split or demonstrating sustained share price improvement.
- Compliance Deadline: The NYSE American has set a deadline of July 5, 2018, for the Company to regain compliance.
- Trading Symbol: While the stock continues to trade under the symbol "IBIO," it will carry an added designation of ".BC" to indicate non-compliance with listing standards.
Outlook, Risks, and Management Commentary
Management stated that the notification does not affect business operations, SEC reporting obligations, or trigger events of default under material agreements. The primary risk identified is the potential delisting if the Company fails to meet the share price requirements or execute a reverse stock split by the July 5, 2018 deadline.
Investor Verification Checklist
- Verify the current share price trend relative to the $1.00 minimum bid price requirement.
- Monitor for announcements regarding a potential reverse stock split before July 5, 2018.
- Confirm the trading symbol now includes the ".BC" suffix on brokerage platforms.
- Review the attached press release (Exhibit 99.1) for additional management commentary.